Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects / Hsien Yuan Lane en Journal of Clinical Psychopharmacology, Año 2002 - Vol. 22 - No. 2 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 2 (Febrero) . - pp. 4-10 Título : Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects Tipo de documento: texto impreso Autores: Hsien Yuan Lane, Autor ; Yue Cune Chang, Autor ; Muh-Hwan Su, Autor Fecha de publicación: 2023 Artículo en la página: pp. 4-10 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Enfermedad de Alzheimer, Antipsicóticos, Demencia Vascular, Haloperidol, Pruebas neuropsicológicas, Agitación psicomotora, Risperidona, Trastornos de la conducta social Resumen: For agitated dementia showing insufficient response to conventional antipsychotics, the feasibility of transition to atypical agents remains unknown. Sixty-two Chinese inpatients with dementia and disruptive behaviors were recruited into an 8-week screening trial of haloperidol. Thirty-five (56%) of them responded insufficiently. Link: ./index.php?lvl=notice_display&id=31087 [artículo] Shifting from haloperidol to risperidone for behavioral disturbances in dementia: safety, response predictors, and mood effects [texto impreso] / Hsien Yuan Lane, Autor ; Yue Cune Chang, Autor ; Muh-Hwan Su, Autor . - 2023 . - pp. 4-10. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2002 - Vol. 22 - No. 2 (Febrero) . - pp. 4-10 Palabras clave: Enfermedad de Alzheimer, Antipsicóticos, Demencia Vascular, Haloperidol, Pruebas neuropsicológicas, Agitación psicomotora, Risperidona, Trastornos de la conducta social Resumen: For agitated dementia showing insufficient response to conventional antipsychotics, the feasibility of transition to atypical agents remains unknown. Sixty-two Chinese inpatients with dementia and disruptive behaviors were recruited into an 8-week screening trial of haloperidol. Thirty-five (56%) of them responded insufficiently. Link: ./index.php?lvl=notice_display&id=31087

---

1 (1 - 1 / 1)